Goserelin Acetate | ICI118630 | CAS#145781-92-6 | LHRH

MedKoo Cat#: 100420 | Name: Goserelin Acetate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Goserelin is a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity. Goserelin binds to and activates pituitary gonadotropin releasing hormone (GnRH) receptors. Prolonged administration of goserelin inhibits the secretion of pituitary gonadotropin, thereby decreasing levels of testosterone (in males) and estradiol (in females). Administration of this agent in a depot formulation may result in the regression of sex hormone-sensitive tumors and a reduction in sex organ size and function.

Chemical Structure

Goserelin Acetate

CAS#145781-92-6 (acetate)

Theoretical Analysis

MedKoo Cat#: 100420

Name: Goserelin Acetate

CAS#: 145781-92-6 (acetate)

Chemical Formula: C61H88N18O16

Exact Mass: 0.0000

Molecular Weight: 1329.49

Elemental Analysis: C, 55.11; H, 6.67; N, 18.96; O, 19.25

Price and Availability

Size	Price	Availability
25mg	USD 225.00	Ready to ship
50mg	USD 350.00	Ready to ship
100mg	USD 585.00	Ready to ship
200mg	USD 1,025.00	Ready to ship
500mg	USD 2,150.00	Ready to ship
1g	USD 3,550.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

65807-02-5 (free base) 145781-92-6 (acetate)

Synonym

ICI118630; ICI-118630; ICI 118630; Goserelin Acetate; brand name: Zoladex.

IUPAC/Chemical Name

(S)-N-((6S,9S,12R,15S,18S,21S,24S)-21-((1H-indol-3-yl)methyl)-1-amino-12-(tert-butoxymethyl)-6-((S)-2-(2-carbamoylhydrazine-1-carbonyl)pyrrolidine-1-carbonyl)-15-(4-hydroxybenzyl)-18-(hydroxymethyl)-25-(1H-imidazol-4-yl)-1-imino-9-isobutyl-8,11,14,17,20,23-hexaoxo-2,7,10,13,16,19,22-heptaazapentacosan-24-yl)-5-oxopyrrolidine-2-carboxamide acetate

InChi Key

IKDXDQDKCZPQSZ-JHYYTBFNSA-N

InChi Code

InChI=1S/C59H84N18O14.C2H4O2/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38;1-2(3)4/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90);1H3,(H,3,4)/t38-,39-,40-,41-,42-,43-,44-,45+,46-;/m0./s1

SMILES Code

OC(C)=O.NC(NCCC[C@H](NC([C@@H](NC([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC1=CNC=N1)NC([C@@H]2CCC(N2)=O)=O)=O)CC3=CNC4=C3C=CC=C4)=O)CO)=O)CC5=CC=C(C=C5)O)=O)COC(C)(C)C)=O)CC(C)C)=O)C(N6CCC[C@H]6C(NNC(N)=O)=O)=O)=N

Appearance

White to off-white solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO and in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Goserelin (free base) Chemical Formula: C59H84N18O14 Exact Mass: 1268.6414 Molecular Weight: 1269.4330 Elemental Analysis: C, 55.82; H, 6.67; N, 19.86; O, 17.64

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#TZC70210

QC Data

View QC data: current batch, Lot#TZC70210

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Goserelin acetate (ICI-118630 acetate) functions as a GnRH agonist.

In vitro activity:

As shown in Fig. 6A, FOXO1 expression was significantly increased (P<0.05) and the goserelin-mediated promotion of apoptosis was abrogated by FOXO1-siRNA (P<0.05; Fig. 6C). As FOXO1 is a downstream target of the PI3K/AKT signaling pathway, the expression of AKT/p-AKT was analyzed. As shown in Fig. 6B, goserelin downregulated p-AKT (Ser473) expression. Meanwhile, the expression of FOXO1 was increased by AKT-siRNA (P<0.05; Fig. 6D). Taken together, these data suggest that goserelin may promote EOC cell apoptosis by upregulating FOXO1 through the PI3K/AKT signaling pathway. Reference: Oncol Rep. 2018 Mar;39(3):1034-1042. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802025/

In vivo activity:

In vivo images of subcutaneous xenograft tumors in nude mice revealed that the subcutaneous xenograft tumor model was constructed successfully (Fig. 7A). TUNEL staining showed that goserelin significantly increased the proportion of apoptotic cells in the subcutaneous xenograft tumors (P<0.05; Fig. 7B and C). In the goserelin group, p-AKT expression was significantly lower, while the expression of FOXO1 and GnRHR were significantly increased compared with the NS group (P<0.05; Fig. 7B and D). Reference: Oncol Rep. 2018 Mar;39(3):1034-1042. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802025/

	Solvent	mg/mL	mM
Solubility
	DMSO	29.0	21.81

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,329.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Zhang N, Qiu J, Zheng T, Zhang X, Hua K, Zhang Y. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway. Oncol Rep. 2018 Mar;39(3):1034-1042. doi: 10.3892/or.2017.6159. Epub 2017 Dec 15. PMID: 29286125; PMCID: PMC5802025.

In vitro protocol:

In vivo protocol:

1: Roach M 3rd, Izaguirre A. Goserelin acetate in combination with radiotherapy for prostate cancer. Expert Opin Pharmacother. 2007 Feb;8(2):257-64. Review. PubMed PMID: 17257094. 2: Tsukagoshi S. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies]. Gan To Kagaku Ryoho. 2002 Sep;29(9):1675-87. Review. Japanese. PubMed PMID: 12355959. 3: Koga H, Naito S. [Goserelin acetate depot, LH-RH agonist; its properties and therapeutic effects in prostate cancer]. Nihon Rinsho. 2000 Jul;58 Suppl:186-90. Review. Japanese. PubMed PMID: 11022711. 4: Goldspiel BR, Kohler DR. Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer. DICP. 1991 Jul-Aug;25(7-8):796-804. Review. PubMed PMID: 1835221.